Related Experiment Video

Updated: Jun 21, 2026

A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis
05:12

A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis

Published on: November 22, 2024

Management of dementia with a cerebrovascular component

Christian Bocti1, Sandra Black, Chris Frank

  • 1Division of Neurology, Department of Medicine, Université de Montréal, Montréal, Quebec, Canada. christian.bocti@umontreal.ca

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|July 15, 2009
PubMed

Insights

Treating hypertension may prevent cognitive decline. Medications like galantamine and donepezil offer symptomatic benefits for dementia linked to cerebrovascular disease (CVD), indicating a proactive approach is needed.

Area of Science:

  • Neurology
  • Geriatrics
  • Cardiology

Background:

  • Cerebrovascular disease (CVD) is increasingly recognized as a key contributor to cognitive decline and dementia.
  • Vascular cognitive impairment (VCI) encompasses the full range of cognitive deficits associated with CVD.
  • VCI highlights the importance of early intervention targeting vascular risk factors.

Purpose of the Study:

  • To review intervention studies for the prevention and symptomatic treatment of dementia related to CVD.
  • To provide evidence-based recommendations for managing cognitive decline in the context of cerebrovascular disease.

Main Methods:

  • Systematic review of intervention studies.
  • Analysis of current literature on pharmacologic and non-pharmacologic therapies.
  • Evaluation of evidence for prevention and symptomatic treatment.

Main Results:

  • Hypertension management shows potential in preventing cognitive decline.
  • Galantamine demonstrates benefits in possible Alzheimer's disease with CVD.
  • Donepezil shows efficacy in treating vascular dementia.
  • Limited empirical support exists for other pharmacological interventions.

Conclusions:

  • A proactive strategy for cognitive decline of vascular origin is essential.
  • Evidence supports interventions for both prevention and symptomatic management of VCI.
  • Further research is needed to explore additional therapeutic avenues.
Abstract

More Related Videos

Comprehensive Endovascular and Open Surgical Management of Cerebral Arteriovenous Malformations14:58

Comprehensive Endovascular and Open Surgical Management of Cerebral Arteriovenous Malformations

Published on: October 20, 2017

Related Concept Videos

Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...